KLLJ Investments
KLLJ Investments
Send Message
KLLJ Investments
Stop FollowingKLLJ Investments
View as an RSS Feed
-
Arena: The Belviq Launch And Why The Short Thesis Is Wrong
- Arena's Recent Outperform Call And A Probability Weighted Valuation
- Arena Breaking Out Ahead Of European Approval
- The Approaching Arena Battle
-
Assessing Arena's Belviq As A Diabesity Drug
- Important Insights For Arena Pharmaceuticals
- Are Qsymia's Launch Challenges A Category Problem?
- The Vivus Exit Continues
- Is Arena The Next Alexion?
-
A Valuation Model For Arena's Belviq
- Why Analysts Still Have It Wrong With Arena
- Is Arena Still A Speculative Stock?
- Preview Of Arena's Upcoming Advisory Committee
- Arena Pharmaceuticals' Lorcaserin Will Be A Blockbuster Drug
-
Weight Loss Drugs: Why Arena's Is Likely To Win Approval Before Vivus's
- Is Arena's Lorcaserin On Track For Approval In 2012?
- VirnetX Is on Fire: Join the Party Before It's Too Late
- Sangamo BioSciences' Platform Could Be the Future of Biotech
- MannKind's Path Forward
- MannKind’s Afrezza Has Mega-Blockbuster Potential
- Clearing Up the Uncertainty Around MannKind’s Afrezza
- Afrezza’s Market Potential and the Future Value of MannKind
- Lorcaserin’s Path to Approval
-
What Analysts Won't Tell You About Arena
- Is Lorcaserin the New Miracle Drug?
- Is Mannkind the Next Takeover Target?
- Arena Inks a Potential Blockbuster Deal
- MannKind Bear Analysts Strike Again
- A Giant Leap for MannKind
- Vivus: Is the Ship Sinking?
- Is Arena’s Lorcaserin More Valuable Than Dendreon’s Provenge?
